Repair compositions and uses thereof

Abstract

The invention provides a repairing composition and application thereof. The repairing composition at least comprises the following components: (1) polydeoxyribonucleotide; (2) gamma-polyglutamic acid or a salt thereof; and (3) hyaluronic acid or salts thereof, and the three components of polydeoxyribonucleotide, gamma-polyglutamic acid or salts thereof and hyaluronic acid or salts thereof in the repairing composition are compounded to achieve a synergistic effect, so that the repairing composition is beneficial to improving skin sensitivity, repairing skin barriers, stimulating collagen regeneration and the like.

Description

Technical Field

[0001] This application relates to the field of food or pharmaceutical technology, and more particularly to a repair composition and its use. Background Technology

[0002] Polydeoxyribonucleotides (PDRN) are renewable substances extracted from salmon reproductive cells, exhibiting a high degree of similarity in base composition to human DNA. PDRN's unique molecular structure endows it with powerful biological activity and stability, promoting cell proliferation and differentiation, accelerating skin tissue repair, and strengthening the skin barrier. PDRN possesses multiple benefits, including anti-inflammatory, tissue repair, anti-melanin production, and anti-aging effects, and is widely used in high-end skincare products and cosmetic injections.

[0003] Sodium hyaluronate (HA) is the sodium salt of hyaluronic acid, a high-molecular-weight linear mucopolysaccharide composed of repeatedly linked N-acetylglucosamine and D-glucuronic acid disaccharide units. Known as a "natural moisturizing factor," sodium hyaluronate possesses excellent moisturizing and skin-repairing properties. It forms a water-locking film on the skin surface, promoting the synthesis of endogenous hyaluronic acid, thereby increasing skin moisture content, improving skin metabolism, and enhancing skin elasticity and radiance. Furthermore, it also repairs damaged tissue, regulates cell proliferation, promotes wound healing, and has antioxidant and anti-aging effects.

[0004] Gamma-polyglutamic acid (GPG) or its salts are biopolymers derived from natto, a food source, and produced through microbial fermentation. GPG or its salts possess strong moisturizing capabilities, absorbing large amounts of water to provide long-lasting hydration to the skin. Furthermore, GPG or its salts can promote collagen production, improving skin elasticity; promote cell regeneration, slowing down the skin aging process; and have antibacterial and anti-inflammatory effects, relieving skin inflammation and redness.

[0005] Polydeoxyribonucleotides can promote the production of hyaluronic acid by fibroblasts and enhance and prolong the effects of hyaluronic acid. γ-polyglutamic acid or its salts can inhibit the activity of hyaluronidase in the skin, improve the stability of hyaluronic acid in the skin, and increase the content of hyaluronic acid. Summary of the Invention

[0006] This application provides a repair composition in which polydeoxyribonucleotides, γ-polyglutamic acid or their salts and hyaluronic acid or their salts can synergistically enhance the effects of improving skin sensitivity, repairing the skin barrier, and stimulating collagen regeneration.

[0007] The specific technical solution of this application is as follows:

[0008] This application provides a repair composition comprising at least the following components:

[0009] (1) Polydeoxyribonucleotides;

[0010] (2) γ-polyglutamic acid or its salt;

[0011] (3) Hyaluronic acid or its salt.

[0012] Further, the mass ratio of the polydeoxyribonucleotide: γ-polyglutamic acid or its salt: hyaluronic acid or its salt is (0.5-1.5):(0.5-1.5):(0.6-2.0).

[0013] Furthermore, the weight-average molecular weight of the hyaluronic acid or its salt is 500kDa-2400kDa, preferably 1300kDa-1800kDa.

[0014] Furthermore, the molecular weight of the polydeoxyribonucleotide is 100kDa-1000kDa.

[0015] Furthermore, the molecular weight of the γ-polyglutamic acid or its salt is 500kDa-1500kDa, preferably 700kDa-1500kDa.

[0016] Further, based on the mass percentage of the repair composition, the polydeoxyribonucleotide is 0.5-1.5%, the γ-polyglutamic acid or its salt is 0.5-1.5%, and the hyaluronic acid or its salt is 0.6-2.0%.

[0017] This application provides a method for preparing the above-mentioned repair composition, comprising:

[0018] Dissolve the hyaluronic acid or its salt and γ-polyglutamic acid or its salt to obtain solution A;

[0019] The polydeoxyribonucleotide was dissolved to obtain solution B;

[0020] The solutions A and B are mixed evenly to obtain the repair composition.

[0021] Furthermore, the pH of the repair composition is 6-7.6.

[0022] This application also provides the use of the above-described repair composition in the preparation of products that improve skin sensitivity, repair the skin barrier, and / or stimulate collagen regeneration.

[0023] The effects of the invention

[0024] The repair composition provided in this application is used to improve skin condition. The three components in the composition, polydeoxyribonucleotide, γ-polyglutamic acid or its salt, and hyaluronic acid or its salt, work together to achieve a synergistic effect, which is beneficial to improve skin sensitivity, repair the skin barrier, and stimulate collagen regeneration. Detailed Implementation

[0025] The present application will now be described in detail with reference to the described embodiments. Although specific embodiments of the present application are shown, it should be understood that the present application can be implemented in various forms and should not be limited to the embodiments set forth herein. Rather, these embodiments are provided so that this application will be thorough and complete, and will fully convey the scope of the present application to those skilled in the art.

[0026] It should be noted that certain terms are used in the specification and claims to refer to specific components. Those skilled in the art will understand that different terms may be used to refer to the same component. This specification and claims do not distinguish components based on differences in terminology, but rather on differences in function. The terms "comprising" or "including" used throughout the specification and claims are open-ended and should be interpreted as "comprising but not limited to." The following descriptions in the specification are preferred embodiments for carrying out this application; however, these descriptions are for the purpose of understanding the general principles of the specification and are not intended to limit the scope of this application. The scope of protection of this application shall be determined by the appended claims.

[0027] This application provides a repair composition comprising at least the following components:

[0028] (1) Polydeoxyribonucleotides;

[0029] (2) γ-polyglutamic acid or its salt;

[0030] (3) Hyaluronic acid or its salt.

[0031] The repair composition described in this application contains polydeoxyribonucleotides, γ-polyglutamic acid or its salts, and hyaluronic acid or its salts. The three work synergistically to improve skin sensitivity, repair the skin barrier, and stimulate collagen regeneration.

[0032] In some embodiments, the mass ratio of the polydeoxyribonucleotide: γ-polyglutamic acid or its salt: hyaluronic acid or its salt is (0.5-1.5):(0.5-1.5):(0.6-2.0).

[0033] For example, the mass ratio of polydeoxyribonucleotide: γ-polyglutamic acid or its salt: hyaluronic acid or its salt (m) 多聚脱氧核糖核苷酸 :m γ-聚谷氨酸或其盐 :m 透明质酸或其盐The possible values ​​are 0.5:0.5:0.6, 0.5:0.7:0.6, 0.5:0.8:0.6, 0.5:0.9:0.6, 0.5:1.0:0.6, 0.5:1.1:0.6, 0.5:1.2:0.6, 0.5:1.3:0.6, 0.5:1.4:0.6, 0.5:1.5:0.6, 0.5:1.0:0.7, 0.5:1.0:0.8, 0.5:1.0:0.9, 0.5:1.0:1.0, 0.5: 1.0:1.1, 0.5:1.0:1.2, 0.5:1.0:1.3, 0.5:1.0:1.4, 0.5:1.0:1.5, 0.6:1.0:1.5, 0.7:1.0:1.5, 0.8:1.0:1.5, 0.9:1.0:1.5, 1.0:1.0:1.5, 1.1:1.0:1.5, 1.2:1.0:1.5, 1.3:1.0:1.5, 1.4:1.0:1.5, 1.5:1.0:1.5, etc.

[0034] In some embodiments, the weight-average molecular weight of the hyaluronic acid or its salt is 500kDa-2400kDa, preferably 1300kDa-1800kDa.

[0035] For example, the molecular weight of the hyaluronic acid or its salt can be 500kDa, 600kDa, 700kDa, 800kDa, 900kDa, 1000kDa, 1100kDa, 1200kDa, 1300kDa, 1400kDa, 1500kDa, 1600kDa, 1700kDa, 1800kDa, 1900kDa, 2000kDa, 2100kDa, 2200kDa, 2300kDa, 2400kDa, etc.

[0036] In this application, no restrictions are placed on the method for determining the weight-average molecular weight of hyaluronic acid or its salts. Those skilled in the art can use conventional methods in the field to perform the determination, such as gel permeation chromatography (GPC), viscosity method, or laser light scattering method.

[0037] In this application, no limitation is made in the art regarding hyaluronic acid salts, which can be any metal salt of hyaluronic acid, such as sodium hyaluronate, potassium hyaluronate, calcium hyaluronate, magnesium hyaluronate, zinc hyaluronate, etc.

[0038] In some embodiments, the weight-average molecular weight of the γ-polyglutamic acid or its salt is 500kDa-1500kDa, preferably 700kDa-1500kDa.

[0039] For example, the molecular weight of the γ-polyglutamic acid or its salt can be 500kDa, 550kDa, 600kDa, 650kDa, 700kDa, 750kDa, 800kDa, 850kDa, 900kDa, 950kDa, 1000kDa, 1050kDa, 1100kDa, 1150kDa, 1200kDa, 1250kDa, 1300kDa, 1350kDa, 1400kDa, 1450kDa, 1500kDa, etc.

[0040] In this application, no limitation is made in the art regarding γ-polyglutamate salts, which can be any metal salt of γ-polyglutamate, such as sodium γ-polyglutamate, potassium γ-polyglutamate, calcium γ-polyglutamate, magnesium γ-polyglutamate, zinc γ-polyglutamate, etc.

[0041] In this application, no restrictions are placed on the method for determining the molecular weight of γ-polyglutamic acid or its salts. Those skilled in the art can use conventional methods in the field to determine it, such as the viscosity method.

[0042] In some embodiments, the molecular weight of the polydeoxyribonucleotide is 100kDa-1000kDa.

[0043] For example, the molecular weight of the polydeoxyribonucleotide can be 100kDa, 150kDa, 200kDa, 250kDa, 300kDa, 350kDa, 400kDa, 450kDa, 500kDa, 550kDa, 600kDa, 650kDa, 700kDa, 750kDa, 800kDa, 850kDa, 900kDa, 950kDa, 1000kDa, etc.

[0044] In this application, no restrictions are placed on the method for determining the molecular weight of polydeoxyribonucleotides. Those skilled in the art can use conventional methods in the field to determine the molecular weight, such as the gel permeation chromatography-laser light scattering (GPC-MALLS) method.

[0045] In some embodiments, the polydeoxyribonucleotide is 0.5-1.5% by mass percentage in the repair composition, the γ-polyglutamic acid or a salt thereof is 0.5-1.5% by mass percentage, and the hyaluronic acid or a salt thereof is 0.6-2.0% by mass percentage.

[0046] For example, the polydeoxyribonucleotide can be 0.5%, 0.6%, 0.7%, 0.8%, 0.9%, 1.0%, 1.1%, 1.2%, 1.3%, 1.4%, 1.5%, etc., based on its mass percentage in the repair composition;

[0047] The γ-polyglutamic acid or its salt may be 0.5%, 0.6%, 0.7%, 0.8%, 0.9%, 1.0%, 1.1%, 1.2%, 1.3%, 1.4%, 1.5%, etc.;

[0048] The hyaluronic acid or its salt may be 0.5%, 0.6%, 0.7%, 0.8%, 0.9%, 1.0%, 1.1%, 1.2%, 1.3%, 1.4%, 1.5%, 1.6%, 1.7%, 1.8%, 1.9%, 2.0%, etc.

[0049] The polydeoxyribonucleotides in the repair composition described in this application can promote the production of hyaluronic acid, enhancing and prolonging its effects; γ-polyglutamic acid or its salts can inhibit the activity of hyaluronidase in the skin, improving the stability of hyaluronic acid in the skin and increasing its content. While fully utilizing the efficacy of individual components, the repair composition also exhibits a synergistic effect, resulting in superior efficacy compared to single components. It demonstrates good results in improving skin sensitivity, repairing the skin barrier, and stimulating collagen regeneration.

[0050] This application provides a method for preparing the above-described repair composition, comprising:

[0051] Dissolve the hyaluronic acid or its salt and γ-polyglutamic acid or its salt to obtain solution A;

[0052] The polydeoxyribonucleotide was dissolved to obtain solution B;

[0053] The solutions A and B are mixed evenly to obtain the repair composition.

[0054] In this application, there is no specific order in which the steps for preparing solution A and solution B are performed.

[0055] In some embodiments, the pH of the repair composition is 6-7.6.

[0056] For example, the pH of the repair composition can be 6.0, 6.1, 6.2, 6.3, 6.4, 6.5, 6.6, 6.7, 6.8, 6.9, 7.0, 7.1, 7.2, 7.3, 7.4, 7.5, 7.6, etc.

[0057] In this application, no restrictions are placed on the method for determining the pH of the repair composition; conventional methods in the art can be used for determination.

[0058] In this application, solutions A and B can be prepared by dissolving the hyaluronic acid or its salt, γ-polyglutamic acid or its salt, and polydeoxyribonucleotides in a water washing solution to obtain solutions A and B, respectively.

[0059] In this application, the washing solution may be, for example, water for injection, physiological saline, phosphate-sodium chloride buffer, etc.

[0060] In some embodiments, mixing A and solution B uniformly involves adding solution B to solution A and stirring to obtain the repair composition.

[0061] In some embodiments, the repair composition is a sterile composition. Preferably, the repair composition is sterilized by moist heat sterilization. Preferably, the temperature of the moist heat sterilization is 121°C and F0 = 8.

[0062] This application provides the use of the above-described composition in the preparation of products that improve skin sensitivity, repair the skin barrier, and / or stimulate collagen regeneration.

[0063] Example

[0064] This application provides a general and / or specific description of the materials and methods used in the experiments. In the following examples, unless otherwise specified, % represents wt%, i.e., weight percentage. Reagents and instruments used, unless otherwise specified, are all commercially available conventional products. Polydeoxyribonucleotides were purchased from Bloomage Biotechnology (Weihai) Co., Ltd. TM -Haiyue), sodium hyaluronate was purchased from Bloomage Biotechnology Co., Ltd. TM Hyatrue), sodium γ-polyglutamate was purchased from Bloomage Biotechnology Co., Ltd. (Hyafactor) TM -PGA).

[0065] Example 1: Preparation of the Repair Composition

[0066] (1) Weigh 1.5g of sodium hyaluronate (molecular weight 1500kDa) and 1.0g of sodium γ-polyglutamate (molecular weight 1300kDa), add an appropriate amount of sodium chloride phosphate buffer solution to 80g, stir until completely dissolved, and obtain solution A;

[0067] (2) Weigh 1.0g of polydeoxyribonucleotide (molecular weight 150kDa), add an appropriate amount of water for injection to 20g, stir until completely dissolved, and obtain solution B;

[0068] The preparation of solution A and solution B can be performed in any order.

[0069] (3) Slowly transfer solution B to solution A, stir evenly, adjust the pH of the solution to 7.1, and sterilize at 121℃ and F0=8 to obtain the composition.

[0070] Preparation of Repair Compositions in Examples 2-6

[0071] The preparation methods of Examples 2-6 are the same as those of Example 1, except for the amount of sodium hyaluronate, the amount of sodium γ-polyglutamate, the molecular weight, and the amount and molecular weight of polydeoxyribonucleotides, as detailed in Table 1.

[0072] Example 7 Preparation of the Repair Composition

[0073] The difference between Example 7 and Example 1 is that the molecular weight of sodium hyaluronate is different, as shown in Table 1.

[0074] Example 8: Preparation of the Repair Composition

[0075] The difference between Example 8 and Example 1 is that the molecular weight of sodium hyaluronate is different, as shown in Table 1.

[0076] Examples 9-10: Preparation of the Repair Composition

[0077] The difference between Examples 9-10 and Example 1 is that the molecular weight of sodium hyaluronate is different, as shown in Table 1.

[0078] Example 11

[0079] (1) Weigh 5g of sodium hyaluronate (1500kDa) and 5g of sodium γ-polyglutamate (molecular weight 1300kDa), add an appropriate amount of sodium chloride phosphate buffer solution to 80g, stir until completely dissolved, and obtain solution A;

[0080] (2) Weigh 1g of polydeoxyribonucleotide (molecular weight 150kDa), add an appropriate amount of water for injection to 20g, stir until completely dissolved, and obtain solution B;

[0081] The preparation of solution A and solution B can be performed in any order.

[0082] (3) Slowly transfer solution B to solution A, stir evenly, adjust the pH of the solution to 7.1, and sterilize at 121℃ and F0=8 to obtain the composition.

[0083] Comparative Example 1

[0084] Weigh 1.0g of polydeoxyribonucleotide (molecular weight 150kDa), add an appropriate amount of water for injection to 100g, stir until completely dissolved, adjust the pH of the solution to 7.1, and sterilize at 121℃ and F0=8 to obtain the composition.

[0085] Comparative Example 2

[0086] Weigh 0.5g of polydeoxyribonucleotide (molecular weight 150kDa), add an appropriate amount of water for injection to 100g, stir until completely dissolved, adjust the pH of the solution to 7.1, and sterilize at 121℃ and F0=8 to obtain the composition.

[0087] Comparative Example 3

[0088] Weigh 1.5g of polydeoxyribonucleotide (molecular weight 150kDa), add an appropriate amount of water for injection to 100g, stir until completely dissolved, adjust the pH of the solution to 7.1, and sterilize at 121℃ and F0=8 to obtain the composition.

[0089] Comparative Example 4

[0090] Weigh 1.5g of sodium hyaluronate (molecular weight 1500kDa), add an appropriate amount of sodium chloride phosphate buffer solution to 100g, stir until completely dissolved, adjust the pH of the solution to 7.1, and sterilize at 121℃ and F0=8 to obtain the composition.

[0091] Comparative Example 5

[0092] Weigh 2.0g of sodium hyaluronate (molecular weight 1500kDa), add an appropriate amount of sodium chloride phosphate buffer solution to 100g, stir until completely dissolved, adjust the pH of the solution to 7.1, and sterilize at 121℃ and F0=8 to obtain the composition.

[0093] Comparative Example 6

[0094] Weigh 0.6g of sodium hyaluronate (molecular weight 1500kDa), add an appropriate amount of sodium chloride phosphate buffer solution to 100g, stir until completely dissolved, adjust the pH of the solution to 7.1, and sterilize at 121℃ and F0=8 to obtain the composition.

[0095] Comparative Example 7

[0096] Weigh 1.0g of sodium γ-polyglutamate (molecular weight 1300kDa), add an appropriate amount of phosphate-sodium chloride buffer solution to 100g, stir until completely dissolved, adjust the pH of the solution to 7.1, and sterilize at 121℃ and F0=8 to obtain the composition.

[0097] Comparative Example 8

[0098] Weigh 0.5g of sodium γ-polyglutamate (molecular weight 1300kDa), add an appropriate amount of phosphate-sodium chloride buffer solution to 100g, stir until completely dissolved, adjust the pH of the solution to 7.1, and sterilize at 121℃ and F0=8 to obtain the composition.

[0099] Comparative Example 9

[0100] Weigh 1.5g of sodium γ-polyglutamate (molecular weight 1300kDa), add an appropriate amount of phosphate-sodium chloride buffer solution to 100g, stir until completely dissolved, adjust the pH of the solution to 7.1, and sterilize at 121℃ and F0=8 to obtain the composition.

[0101] Comparative Example 10

[0102] Weigh 1.5g of sodium hyaluronate (molecular weight 1300kDa), add an appropriate amount of sodium chloride phosphate buffer solution to 100g, stir until completely dissolved, adjust the pH of the solution to 7.1, and sterilize at 121℃ and F0=8 to obtain the composition.

[0103] Comparative Example 11

[0104] Weigh 1.5g of sodium hyaluronate (molecular weight 1800kDa), add an appropriate amount of phosphate-sodium chloride buffer solution to 100g, stir until completely dissolved, adjust the pH of the solution to 7.1, and sterilize at 121℃ and F0=8 to obtain the composition.

[0105] Comparative Example 12

[0106] Weigh 1.5g of sodium hyaluronate (molecular weight 200kDa), add an appropriate amount of sodium chloride phosphate buffer solution to 100g, stir until completely dissolved, adjust the pH of the solution to 7.1, and sterilize at 121℃ and F0=8 to obtain the composition.

[0107] Comparative Example 13

[0108] Weigh 1.5g of sodium hyaluronate (molecular weight 2600kDa), add an appropriate amount of sodium chloride phosphate buffer solution to 100g, stir until completely dissolved, adjust the pH of the solution to 7.1, and sterilize at 121℃ and F0=8 to obtain the composition.

[0109] Comparative Example 14

[0110] Weigh 5.0g of sodium hyaluronate (molecular weight 1500kDa), add an appropriate amount of sodium chloride phosphate buffer solution to 100g, stir until completely dissolved, adjust the pH of the solution to 7.1, and sterilize at 121℃ and F0=8 to obtain the composition.

[0111] Comparative Example 15

[0112] Weigh 5.0g of sodium γ-polyglutamate (molecular weight 1300kDa), add an appropriate amount of sodium chloride phosphate buffer solution to 100g, stir until completely dissolved, adjust the pH of the solution to 7.1, and sterilize at 121℃ and F0=8 to obtain the composition.

[0113] Table 1

[0114]

[0115] Experimental Example

[0116] 1. Anti-inflammatory efficacy test

[0117] The anti-inflammatory effects of different compositions were evaluated by establishing an in vitro cell model using lipopolysaccharide (LPS) (Beijing Solarbio Science & Technology Co., Ltd.) to stimulate mouse macrophages.

[0118] First, prepare the LPS solution by weighing 5 mg of LPS powder and dissolving it in 1 mL of DMEM high-glucose basal medium (Wuhan Pronosai Biotechnology Co., Ltd.) containing 10% fetal bovine serum. Mix well and filter through a 0.22 μm filter membrane to obtain a 5 mg / mL stock solution, which should be stored at -20°C. Dilute to 1 μg / mL with culture medium before use. Take Raw264.7 mouse mononuclear macrophages (Wuhan Pronosai Biotechnology Co., Ltd.) in the logarithmic growth phase and use 1×10⁻⁶ LPS powder to prepare the LPS solution. 5 Cells were seeded at a density of 1 / mL in 24-well plates and cultured at 37°C and 5% CO2 for 24 h. Different groups of composite samples were added, 1 mL per well, with physiological saline added to the blank group. After another 24 h of culture, the changes in IL-6 and TNF-α levels in the cells were detected using an ELISA kit. The results are shown in Table 2.

[0119] IL-6 content change rate % = (IL-6 content in sample group - IL-6 content in blank group) / IL-6 content in blank group * 100%.

[0120] TNF-α content change rate % = [(TNF-α content in sample group - TNF-α content in blank group) / TNF-α content in blank group] * 100%.

[0121] The lower the percentage change in IL-6 content and the percentage change in TNF-α content, the better the anti-inflammatory effect.

[0122] Table 2

[0123]

[0124]

[0125] To illustrate that the components in the anti-aging composition provided in this application have a synergistic effect, and are not merely a simple sum of the effects of the components, this application uses the COLBY formula: E 理论The formula =|X|+|Y|+|Z|-(|X*Y|+|X*Z|+|Y*Z|) / 100+|X*Y*Z| / 10000 was used for verification, where X, Y, and Z are the percentage changes in IL-6 or TNF-α content, respectively, for single-component treatment. 理论 The percentage change in theoretical IL-6 content or TNF-α content after treatment with the composition is %. |E 实际 | represents the percentage change in actual IL-6 content or TNF-α content after treatment with the composition; |E 实际 |>E 理论 To improve efficiency; |E 实际 |<E 理论 For antagonism; |E 实际 |=E 理论 For addition.

[0126] In this embodiment, the E theory of Example 1 was calculated from the data of Comparative Examples 1, 7, and 4; the E theory of Example 2 was calculated from the data of Comparative Examples 2, 7, and 4; the E theory of Example 4 was calculated from the data of Comparative Examples 1, 8, and 4; the E theory of Example 5 was calculated from the data of Comparative Examples 2, 8, and 5; the E theory of Example 6 was calculated from the data of Comparative Examples 3, 9, and 6; the E theory of Example 7 was calculated from the data of Comparative Examples 1, 7, and 10; the E theory of Example 8 was calculated from the data of Comparative Examples 1, 7, and 11; the E theory of Example 9 was calculated from the data of Comparative Examples 1, 7, and 12; the E theory of Example 10 was calculated from the data of Comparative Examples 1, 7, and 13; and the E theory of Example 11 was calculated from the data of Comparative Examples 1, 15, and 14.

[0127] The results of the synergistic effect determination are shown in Table 3 below.

[0128] Table 3

[0129]

[0130]

[0131] 2. Repair Efficacy Test

[0132] The effects of different sample groups on the migration ability of L929 mouse fibroblasts were investigated by scratch assay to evaluate the repair effect of the samples.

[0133] Mouse fibroblasts L929 (Wuhan Pronosei Biotechnology Co., Ltd.) in the logarithmic growth phase were used at a concentration of 3 × 10⁻⁶. 5Cells were seeded at a density of 1 / mL in 24-well plates and cultured at 37°C and 5% CO2 for 24 h. Different groups of composite samples were then added, 1 mL per well, with physiological saline added to the blank group. Cells were cultured for another 36 h, and cell migration was observed under an inverted microscope. The results are shown in Table 4, with cell migration rate analyzed using ImageJ software.

[0134] Cell migration rate (%) = [1 - (scratch area after sample addition / initial scratch area)] × 100%.

[0135] Table 4

[0136]

[0137]

[0138] The results show that the combination of polydeoxyribonucleotides, γ-polyglutamic acid or its salts, and sodium hyaluronate has a much higher repair effect than the combination of polydeoxyribonucleotides, γ-polyglutamic acid or its salts, and sodium hyaluronate alone. The composition of this application can play a synergistic role in promoting repair.

[0139] 3. Tests to promote collagen regeneration

[0140] Human skin fibroblasts HSF (Shanghai Fuheng Biotechnology Co., Ltd.) were processed at a rate of 2 × 10⁻⁶. 5 Type I collagen was seeded at a concentration of 1 / mL in 24-well plates and incubated at 37°C and 5% CO2 for 24 h. Different groups of composite samples were then added, 1 mL per well, with physiological saline added to the blank group. The culture was continued for another 24 h, and the supernatant was collected. The content of type I collagen in the supernatant was detected using an ELISA kit, and the rate of change in content was calculated. The results are shown in Table 5.

[0141] Change rate of type I collagen content % = [(Type I collagen content in the sample group - Type I collagen content in the blank group) / Type I collagen content in the blank group] * 100%.

[0142] Table 5. Change rate of type I collagen content (%)

[0143]

[0144]

[0145] The results showed that the combination of polydeoxyribonucleotides, γ-polyglutamic acid or its salts, and sodium hyaluronate can play a synergistic role, and its repair effect is far higher than that of polydeoxyribonucleotides, γ-polyglutamic acid or its salts, or sodium hyaluronate alone, or the simple sum of the effects of the three.

[0146] The above description is merely a preferred embodiment of this application and is not intended to limit the application in any other way. Any person skilled in the art may make changes or modifications to the disclosed technical content to create equivalent embodiments. However, any simple modifications, equivalent changes, and modifications made to the above embodiments based on the technical essence of this application without departing from the scope of the technical solution of this application shall still fall within the protection scope of this application.

Claims

1. A repair composition comprising at least the following components: (1) Polydeoxyribonucleotides; (2) γ-polyglutamic acid or its salt; (3) Hyaluronic acid or its salt.

2. The repair composition according to claim 1, wherein, The mass ratio of the polydeoxyribonucleotide: γ-polyglutamic acid or its salt: hyaluronic acid or its salt is (0.5-1.5):(0.5-1.5):(0.6-2.0).

3. The repair composition according to claim 1 or 2, wherein, The weight-average molecular weight of the hyaluronic acid or its salt is 500kDa-2400kDa.

4. The repair composition according to any one of claims 1-3, wherein the polydeoxyribonucleotide has a molecular weight of 100kDa-1000kDa.

5. The repair composition according to any one of claims 1-4, wherein the polydeoxyribonucleotide is 0.5-1.5% by mass percentage in the repair composition, the γ-polyglutamic acid or a salt thereof is 0.5-1.5%, and the hyaluronic acid or a salt thereof is 0.6-2.0%.

6. A method for preparing the repair composition according to any one of claims 1-5, comprising: Dissolve the hyaluronic acid or its salt and γ-polyglutamic acid or its salt to obtain solution A; The polydeoxyribonucleotide was dissolved to obtain solution B; The solutions A and B are mixed evenly to obtain the repair composition.

7. The method according to claim 6, wherein, The pH of the repair composition is 6-7.

6.

8. Use of the composition according to claims 1-5 in the preparation of products that improve skin sensitivity, repair the skin barrier and / or stimulate collagen regeneration.

Images